Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.32011 ↗At a glance
Journal article in Pediatric Blood & Cancer, 2025. Written by Lev Gorfinkel and 3 co-authors. Institution: Dana-Farber and Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Recombinant Fusion Proteins, Thrombopoietin, Thrombocytopenia, Receptors, Fc. Cited 2 times so far (Crossref); 26 references.
Topics: Onkologische Pflege
Abstract (original language)
Romiplostim for chemotherapy‐induced thrombocytopenia (CIT) is not well‐studied in children. This single‐center retrospective cohort study describes 24 pediatric patients with solid tumors who initiated romiplostim a median of 5 months into chemotherapy (range: 0–14 months) at a median maximum dose of 6.5 µg/kg (range: 1–10). A minority of patients achieved a decrease in cycle delays (30%) or dose reductions (13%). A comparative cohort, which did not receive romiplostim, had no difference in cycle delays ( p = 0.42) or dose reductions ( p > 0.99). There were no adverse events. Romiplostim was safe in children with solid tumors, but requires further prospective study of efficacy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Dana-Farber and Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, USA.
ORCID profiles: Lev Gorfinkel, Emily M Harris, Allison F O'Neill
Cite
APA
Gorfinkel, L., Harris, E. M., Wall, C. B., & O'Neill, A. F. (2025). Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32011
Vancouver
Gorfinkel L, Harris EM, Wall CB, O'Neill AF. Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.32011
BibTeX
@article{Gorfinkel2025,
author = {Gorfinkel, Lev and Harris, Emily M and Wall, Catherine B and O'Neill, Allison F},
title = {Romiplostim for Chemotherapy‐Induced Thrombocytopenia: A Case Cohort Assessment of Safety, Efficacy, and Proposed Future Study in Pediatric Patients With Solid Tumors},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.32011}
}
EUVIMED